Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20 participants
OBSERVATIONAL
2025-06-01
2030-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amyotrophic Lateral Sclerosis: a New Paradigm
NCT03073239
Muscular Biomarkers in Amyotrophic Lateral Sclerosis
NCT02670226
ALS Research Collaborative
NCT06885918
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
NCT07143656
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
NCT01495390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALS Cohort
Patients of Dr. Espíndola at UFSC that are diagnosed with ALS and meet the inclusion/exclusion criteria.
No interventions assigned to this group
Control Cohort
Those that meet the inclusion/exclusion criteria, do not have ALS, and generally are healthy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal de Santa Catarina
OTHER
Viome
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
V234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.